A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis.

Trial Profile

A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Etrolizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 02 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2014 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
    • 04 Nov 2014 Status changed from active, no longer recruiting to recruiting, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top